OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in HIV and AIDS is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial introductions	51
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	38
The sounds of silencing: dynamic epigenetic control of HIV latency	35
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	34
Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research	33
Future options for long-acting HIV treatment and prevention	30
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	29
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure	27
Editorial introductions	26
Harnessing natural killer cells to target HIV-1 persistence	25
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	24
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	24
Editorial introduction	23
New latency-promoting agents for a block-and-lock functional cure strategy	22
Challenges towards an AIDS-free generation in Africa and Asia	20
Editorial introduction	19
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	19
Pulse check: modern strategies for cardiovascular risk in women with detection and prevention in women with HIV	17
Persistent elite controllers as the key model to identify permanent HIV remission	16
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	16
The double burden: navigating HIV co-infections with HCV, HBV, and Mtb	16
Public health surveillance and outbreak preparedness for mpox	15
Loneliness and social isolation in people with HIV	15
Editorial introduction	15
Estrogen depletion and immune activation and inflammation in women with HIV	15

A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	15
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	14
Stigma as a facilitator of the 2022 mpox outbreak	14
The origins of new SARS-COV-2 variants in immunocompromised individuals	14
Defining multimorbidity in people with HIV – what matters most?	13
Integrating substance use services into HIV care: an underused implementation science opportunity	13
Balancing polypharmacy and comorbidity management: cardiovascular health	13
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	13
Editorial introduction	13
Impact of coronavirus disease 2019 on co-morbidities in HIV	13
Aging of adult lifetime survivors with perinatal HIV	12
Viral and immune predictors of HIV posttreatment control	12
Role of follicular homing natural killer cells in HIV infection	12
Mpox and the impact on people with HIV	12
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	12
New vector and vaccine platforms: mRNA, DNA, viral vectors	12
Obesity among women with HIV	12
The multifaceted nature of HIV tissue reservoirs	12
Gender and sex considerations in HIV and bone health	11
Metabolic dysfunction-associated steatotic liver disease in people with HIV	11
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	11
Roadmap for spatial transcriptomics of HIV in tissues	11
Broadly neutralizing antibodies for HIV treatment and cure approaches	11
Single-cell sequencing technologies: a multiomics toolbox for investigating HIV-1 persistence	10
Use of implementation theories, models, and frameworks in PrEP implementation research from 2022–2025: innovation and participation	10
Host factors predisposing to kidney disease in people with HIV	10
The severity of COVID-19 across the spectrum of HIV	10
Maintain the gains: methods to evaluate the sustainability and scalability of HIV-related prevention, care, and treatment programs	10
Editorial introduction	9
HIV drug resistance in various body compartments	9
Editorial introductions	9
Editorial introductions	9
HIV and cardiovascular disease: the role of inflammation	9
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	8
Strategies to target the central nervous system HIV reservoir	8
Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance	8
Persistent HIV-1 transcription during ART: time to reassess its significance?	8
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Contemporary issues in gynecologic and reproductive health for women with HIV	7
BACH2 effector-to-memory switch promotes HIV persistence and CAR-T efficacy	7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
The pathogenesis of obesity in people living with HIV	7
Mpox in 2026: what we knew, what we have learned, and what we still have to learn	7
Editorial introductions	7
Editorial introductions	7
HIV-1 subtypes and latent reservoirs	7
Causes and outcomes of hepatic fibrosis in persons living with HIV	7
Innovative models of care supporting people aging with HIV	7
Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics	7
Innate immune mechanisms in HIV elite controllers	7